43 related articles for article (PubMed ID: 18704310)
1. Targeted reversal of multidrug resistance in ovarian cancer cells using exosome‑encapsulated tetramethylpyrazine.
Zhao C; Qiu L; Wu D; Zhang M; Xia W; Lv H; Cheng L
Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38099342
[TBL] [Abstract][Full Text] [Related]
2. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
3. Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.
Hsieh CH; Chen YJ; Tsai TH; Wang LY; Tai HC; Huang HL; Huang YC
Sci Rep; 2020 Jun; 10(1):9575. PubMed ID: 32533042
[TBL] [Abstract][Full Text] [Related]
4. Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways.
Guo X; Ding X
Oncol Lett; 2018 Jun; 15(6):9537-9542. PubMed ID: 29805675
[TBL] [Abstract][Full Text] [Related]
5. EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma.
Mohamad T; Kazim N; Adhikari A; Davie JK
Oncotarget; 2018 Apr; 9(26):18084-18098. PubMed ID: 29719592
[TBL] [Abstract][Full Text] [Related]
6. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
7. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.
Villar VH; Vögler O; Martínez-Serra J; Ramos R; Calabuig-Fariñas S; Gutiérrez A; Barceló F; Martín-Broto J; Alemany R
PLoS One; 2012; 7(5):e37735. PubMed ID: 22662203
[TBL] [Abstract][Full Text] [Related]
9. Autophagy in cancer resistance to paclitaxel: Development of combination strategies.
Škubník J; Svobodová Pavlíčková V; Ruml T; Rimpelová S
Biomed Pharmacother; 2023 May; 161():114458. PubMed ID: 36889112
[TBL] [Abstract][Full Text] [Related]
10. Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells.
Lu M; Xiao L; Hu J; Deng S; Xu Y
J Huazhong Univ Sci Technolog Med Sci; 2008 Aug; 28(4):451-5. PubMed ID: 18704310
[TBL] [Abstract][Full Text] [Related]
11. [Study of the relationship between early growth response gene 1 activity in p38 mitogen-activated protein kinase pathway and epirubicin resistance of human breast carcinoma cells].
Xiao L; Hu JL; Cui W
Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):408-13. PubMed ID: 19781349
[TBL] [Abstract][Full Text] [Related]
12. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells.
Lu M; Xiao L; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):725-8. PubMed ID: 18231754
[TBL] [Abstract][Full Text] [Related]
13. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
14. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].
Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
